Clinical trial
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18]…
NCT00337428 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00337428 |
|---|---|
| Title | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) |
| Official title | An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With REPEVAX™ in Healthy Adolescents 11-17 Years of Age |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough, Poliomyelitis |
| Intervention type | Biological |
| Interventions | Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF), 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF), Comparator: REPEVAX™ (Concomitant), Comparator: REPEVAX™ (Non-Concomitant) |
| Enrollment | 843 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jun 16, 2006 |
| Last update posted | Nov 16, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: